These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. The 'never-ending story' of the influence of blood specimen collection methods affecting the concentration, the zymographic profile and the usefulness of matrix metalloproteinases and their tissue inhibitors in multiple sclerosis diagnosis/prognosis: a landmark for limiting the misuse of serum samples. Mannello F; Tonti GA; Canestrari F Mult Scler; 2007 Jun; 13(5):687-90. PubMed ID: 17548455 [No Abstract] [Full Text] [Related]
24. Matrix metalloproteinases in blood from patients with LAM. Odajima N; Betsuyaku T; Nasuhara Y; Inoue H; Seyama K; Nishimura M Respir Med; 2009 Jan; 103(1):124-9. PubMed ID: 18760908 [TBL] [Abstract][Full Text] [Related]
25. Consideration of preanalytical conditions to use circulating matrix metalloproteinases as diagnostic markers. Jung K Transplantation; 2005 Mar; 79(6):744. PubMed ID: 15785392 [No Abstract] [Full Text] [Related]
26. Plasma matrix metalloproteinase activity during the menstrual cycle of healthy ovulatory patients who underwent tubal ligation. Abdallah MA; Nakajima ST; Lin PC; Gercel-Taylor C Fertil Steril; 2005 Dec; 84(6):1766-7. PubMed ID: 16359987 [TBL] [Abstract][Full Text] [Related]
28. Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy. Roldán V; Marín F; Gimeno JR; Ruiz-Espejo F; González J; Feliu E; García-Honrubia A; Saura D; de la Morena G; Valdés M; Vicente V Am Heart J; 2008 Jul; 156(1):85-91. PubMed ID: 18585501 [TBL] [Abstract][Full Text] [Related]
29. Concentrations of circulating gelatinases (matrix metalloproteinase-2 and -9) are dependent on the conditions of blood collection. Meisser A; Cohen M; Bischof P Clin Chem; 2005 Jan; 51(1):274-6. PubMed ID: 15613733 [No Abstract] [Full Text] [Related]
30. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Ahmed SH; Clark LL; Pennington WR; Webb CS; Bonnema DD; Leonardi AH; McClure CD; Spinale FG; Zile MR Circulation; 2006 May; 113(17):2089-96. PubMed ID: 16636176 [TBL] [Abstract][Full Text] [Related]
31. Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis. Klimiuk PA; Sierakowski S; Domyslawska I; Chwiecko J J Rheumatol; 2004 Feb; 31(2):238-42. PubMed ID: 14760791 [TBL] [Abstract][Full Text] [Related]
32. Circulating matrix metalloproteinases and their endogenous inhibitors in patients with erectile dysfunction. Muniz JJ; Lacchini R; Belo VA; Nobre YT; Tucci S; Martins AC; Tanus-Santos JE Int J Impot Res; 2012; 24(1):38-43. PubMed ID: 21918531 [TBL] [Abstract][Full Text] [Related]
33. Matrix metalloproteinases and left ventricular function and structure in spinal cord injured subjects. Schreiber R; Paim LR; de Rossi G; Matos-Souza JR; Costa E Silva Ade A; Souza CM; Borges M; Azevedo ER; Alonso KC; Gorla JI; Cliquet A; Nadruz W Clin Chim Acta; 2014 Nov; 437():136-40. PubMed ID: 25064800 [TBL] [Abstract][Full Text] [Related]
34. Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Niebroj-Dobosz I; Janik P; Sokołowska B; Kwiecinski H Eur J Neurol; 2010 Feb; 17(2):226-31. PubMed ID: 19796283 [TBL] [Abstract][Full Text] [Related]
35. Influence of blood sampling procedure on plasma concentrations of matrix metalloproteinases and their tissue inhibitors. Rossignol P; Cambillau M; Bissery A; Mouradian D; Benetos A; Michel JB; Plouin PF; Chatellier G; Jacob MP Clin Exp Pharmacol Physiol; 2008 Apr; 35(4):464-9. PubMed ID: 18307742 [TBL] [Abstract][Full Text] [Related]
36. Matrix metalloproteinases as novel disease markers in Takayasu arteritis. Matsuyama A; Sakai N; Ishigami M; Hiraoka H; Kashine S; Hirata A; Nakamura T; Yamashita S; Matsuzawa Y Circulation; 2003 Sep; 108(12):1469-73. PubMed ID: 12952836 [TBL] [Abstract][Full Text] [Related]
37. Matrix metalloproteinase circulating levels, genetic polymorphisms, and susceptibility to acute myocardial infarction among patients with coronary artery disease. Hlatky MA; Ashley E; Quertermous T; Boothroyd DB; Ridker P; Southwick A; Myers RM; Iribarren C; Fortmann SP; Go AS; Am Heart J; 2007 Dec; 154(6):1043-51. PubMed ID: 18035073 [TBL] [Abstract][Full Text] [Related]
38. Assessment of matrix metalloproteinase (MMP)-2, MMP-8, MMP-9, and their inhibitors, the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in obese children and adolescents. Belo VA; Souza-Costa DC; Lana CM; Caputo FL; Marcaccini AM; Gerlach RF; Bastos MG; Tanus-Santos JE Clin Biochem; 2009 Jul; 42(10-11):984-90. PubMed ID: 19358835 [TBL] [Abstract][Full Text] [Related]
39. Preanalytical conditions and circulating matrix metalloproteinases. Verspaget HW; Kuyvenhoven JP; van Hoek B Transplantation; 2005 Mar; 79(6):745-6. PubMed ID: 15785393 [No Abstract] [Full Text] [Related]
40. Serum samples are inappropriate for use in measuring circulating matrix metalloproteinases: comment on the article by Young-Min et al. Jung K Arthritis Rheum; 2008 May; 58(5):1557-8; author reply 1559. PubMed ID: 18438823 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]